8 reports

Pancreatic cancer

4546 5000 3864
  • Pipeline: Pancreatic Cancer
  • Forecast: Pancreatic Cancer
  • Cancer
  • Obesity
  • Pancreatic Cancer
  • Therapy
  • Gilead Sciences, Inc.

The Business Research Company January 2018 Oncology Drugs Market Global Briefing 2018 Including: Oncology Drugs, Drugs For Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Colorectal Cancer, Thyr

  • Cancer
  • World
  • Company Financials
  • Forecast
  • Gilead Sciences, Inc.
  • DEVELOPMENT OVERVIEW
  • PRODUCT PROFILE

Cancer Research, (suppl. ) ##, ##s.

  • Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Gilead Sciences, Inc.

CANCER; ##: 2015-2023.

  • Cancer
  • Epidemiology
  • Lymphoma
  • Therapy
  • Gilead Sciences, Inc.
  • ENDPOINT RESULTS FOR DRUGS IN FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA

James Cancer Hos- pital and Richard J.

  • Cancer
  • Lymphoma
  • United States
  • Demand
  • Gilead Sciences, Inc.
  • CANCER GENETICS ENTERS INTO AGREEMENT WITH GILEAD SCIENCES TO PROVIDE CLINICAL TRIAL SERVICES
  • KITE PHARMA ENTERS INTO R&D AGREEMENT WITH NATIONAL CANCER INSTITUTE
  • Cancer
  • Hepatitis Treatment
  • Pharmaceutical
  • Therapy
  • Gilead Sciences, Inc.
  • Products under Development by Companies, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES

It also plans to report Phase III trial data for gastric cancer in third quarter of 2017 and anticipates completion of Phase II study with nivolumab for gastric cancer.

  • Cancer
  • Dermatological Treatment
  • Hospital
  • Therapy
  • Gilead Sciences, Inc.
  • eleclazine
  • Gilead Sciences, Inc. - Dormant Projects

Tesmilifene (YMB##) was under development for the treatment of metastatic or recurrent breast cancer, hepatic cancer, hormone-refractory prostate cancer and gastric cancer.

  • Cancer
  • R&D
  • Research And Development
  • Therapy
  • Gilead Sciences, Inc.